Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:05 PM ET 8-K
Investor Presentation Worthington Enterprises, Inc. WOR

Worthington Enterprises Investor Presentation

Worthington Enterprises hosted an Investor and Analyst Day on November 10, 2026, to discuss its standalone strategy and performance since its separation from the steel processing business. The company introduced updated long-term financial targets and detailed growth opportunities across its Building Performance Solutions and Trade & Specialty Solutions segments.

4:05 PM ET 10-Q
Financial Results AmperCap Acquisition Co APMC

AmperCap Acquisition Q3 2026 Results: Net Income $1.17M

AmperCap Acquisition Co's 10-Q filing for the period ending September 30, 2026, reflects its status as a blank check company with no current operations. The report details administrative expenses and interest income generated from the trust account as the company continues to evaluate potential business combination targets. No definitive merger agreements or significant changes in financial guidance were disclosed.

Key figure
Net income $1.17M
4:05 PM ET 8-K
Financial Results TRex Bio, Inc. TRXB

TRex Bio Financial Results

TRex Bio reported financial results for the third quarter of 2026, highlighting a net loss of $14.1 million and a cash position of $154.2 million. The company recently completed a $133.5 million IPO in October 2026, which extends its expected cash runway into the second half of 2029 to support its clinical pipeline, including TRB-061 and TRB-071.

Term
Q3 2026

“The positive Phase 1a results for TRB-061 demonstrated selective activation and expansion of immunoregulatory Tregs in humans, providing clinical evidence that we believe supports this approach. We are now focused on understanding whether these effects can translate into meaningful and durable disease control for patients with atopic dermatitis.”

Johnston Erwin, Chief Executive Officer of TRexBio

“With the completion of our IPO, we have the resources to advance TRB-061 toward its planned mid-2027 clinical readout and expect to bring TRB-071, which targets a distinct Treg pathway, into the clinic in the first half of 2027.”

Johnston Erwin, Chief Executive Officer of TRexBio
4:05 PM ET 10-Q
Financial Results IRulya Therapeutics Inc. IRLA

IRulya Therapeutics Q3 2026 Results: Net Loss of $27.7M, Loss Widens

IRulya Therapeutics Inc. significantly strengthened its liquidity position in the first nine months of 2026, with cash and short-term investments increasing to $105.2 million from $17.8 million at year-end 2025. The company underwent a major restructuring of its balance sheet, eliminating over $100 million in total liabilities and issuing Series C Preferred Stock valued at $143.8 million following the acquisition of Orphai Therapeutics.

Key figure
Net loss $27.7M
4:05 PM ET 10-Q
Financial Results Propanc Biopharma, Inc. PPCB

Propanc Biopharma Q1 2026 Results: Net Loss of $8.59M, Loss Widens

Propanc Biopharma reported a net loss of $8.6 million for the quarter ended September 30, 2026, compared to a $4.8 million loss in the prior year, driven largely by a significant increase in compensation and professional expenses. The company's cash position decreased to $258,366 from $832,006 at the start of the fiscal year, though it raised $2 million through the exercise of Series C warrants.

Key figure
Net loss $8.59M
4:05 PM ET 10-Q
Financial Results Air Industries Group AIRI

Air Industries Group Q3 2026 Results: Turns Profitable, Net Income $946K

Air Industries Group reported a significant turnaround in the third quarter of 2026, with net sales increasing to $14.6 million and net income reaching $946,000 compared to a loss in the prior year period. However, for the nine months ended September 30, 2026, the company still recorded a net loss of $920,000 despite a 8.7% increase in year-to-date net sales.

Key figure
Net income $946K
4:04 PM ET 8-K
Shareholder Meeting Axos Financial, Inc. AX

Axos Financial Shareholder Meeting

Axos Financial held its 2026 Annual Meeting of Stockholders on November 12, 2026, with 87.81% of eligible shares represented. Stockholders elected three Class I directors (Tamara N. Bohlig, Nicholas A. Mosich, and Edward J. Ratinoff), approved executive compensation in an advisory vote, and ratified BDO USA, P.C. as the independent auditor for fiscal year 2027.

4:04 PM ET 8-K
Leadership Change Adicet Bio, Inc. ACET

Adicet Bio Leadership Change

Dr. Andrew Sinclair resigned from the Board of Directors and its committees effective November 13, 2026, with the board size subsequently reduced from seven to six members. Following the resignation, current director Michael Grissinger was appointed to the Audit Committee and named chairperson of the Nominating and Corporate Governance Committee. The company stated the resignation was not due to any disagreements regarding operations, policies, or practices.

4:04 PM ET 8-K
Business Update Invesco Real Estate Income Trust Inc.

Invesco Real Estate Income Trust Business Update

Invesco Real Estate Income Trust Inc. (INREIT) provided its monthly update for October 31, 2026, reporting a total Net Asset Value (NAV) of approximately $670.2 million. The company disclosed NAV per share across multiple share classes, ranging from $26.06 for Class T to $28.48 for Class E, which will serve as the transaction price for December 1, 2026. The filing details the trust's portfolio composition, including $1.15 billion in real estate investments offset by $480 million in mortgage notes and credit facilities.

4:03 PM ET Form 4
Insider Selling Frontdoor, Inc. FTDR

Frontdoor CEO William C. Cobb Sells $20.4M of Stock

William C. Cobb, CEO, sold 208,747 shares of Frontdoor, Inc. at $96.69 to $99.17 a share (average $97.67) in 3 transactions, worth $20.4M in total between Nov 10, 2026 and Nov 12, 2026. Shares held after the trade: 184,335 (-34.3%).

Value
$20.4M
Shares
208,747
Average price
$97.67
Role
CEO
Holding change
-34.3%
Trade date
Nov 10, 2026 to Nov 12, 2026
4:03 PM ET 8-K
Shareholder Meeting Elicio Therapeutics, Inc. ELTX

Elicio Therapeutics Shareholder Meeting

Elicio Therapeutics held its 2026 Annual Meeting of Stockholders on November 12, 2026. Shareholders elected three Class III directors (Julian Adams, Jay R. Venkatesan, and Carol Ashe) to three-year terms and ratified Baker Tilly US, LLP as the company's independent auditor for the fiscal year ending December 31, 2026.

4:03 PM ET 10-Q
Financial Results Siebert Financial Corp SIEB

Siebert Financial Q3 2026 Results: Net Loss of $711K

Siebert Financial Corp. reported a net loss of $3.0 million for the nine months ended September 30, 2026, compared to a net income of $5.6 million in the prior year period. While total revenue grew to $79.3 million, expenses surged to $83.7 million, driven by higher employee compensation, technology costs, and one-time settlement and impairment charges.

Key figure
Net loss $711K
4:03 PM ET 10-Q
Financial Results SilverBox Corp IV SBXDF

SilverBox Corp IV Q3 2026 Results: Net Income $610K, Down 4.3% YoY

SilverBox Corp IV reported a net income of $3.64 million for the nine months ended September 30, 2026, primarily driven by $4.77 million in interest earned on trust account investments. During the period, the company experienced significant redemptions, with $207.5 million withdrawn from the Trust Account, leaving $10.64 million in investments remaining.

Key figure
Net income $610K · -4.3% YoY
4:03 PM ET 10-Q
Financial Results BioKey (Cayman), Inc.

BioKey Q3 2026 Results: Net Loss of $398K, Loss Widens

BioKey (Cayman), Inc. reported zero revenue for the nine months ended September 30, 2026, with a net loss of $873,721 compared to $538,188 in the prior year period. The company remains heavily dependent on recurring loans from ABVC BioPharma, Inc. to support its operations, with total liabilities reaching $7.56 million against total assets of $1.61 million.

Key figure
Net loss $398K
4:03 PM ET 10-Q
Financial Results Arrive AI Inc. ARAI

Arrive AI Q3 2026 Results: Net Loss of $3.67M, Loss Narrows

Arrive AI Inc. reported a net loss of $24.1 million for the nine months ended September 30, 2026, compared to a $10.1 million loss in the prior year period, driven largely by a $12.3 million loss on the conversion of notes. Total assets decreased to $9.2 million from $10.9 million at year-end 2025, while the company maintained a stockholders' equity of $2.2 million.

Key figure
Net loss $3.67M
4:03 PM ET 10-Q
Financial Results Planet Green Holdings Corp. PLAG

Planet Green Holdings Q3 2026 Results: Net Loss of $454K, Loss Narrows

Planet Green Holdings Corp. reported a significant increase in net revenues to $9.58 million for the nine months ended September 30, 2026, compared to $67,270 in the prior year, though it still incurred a net loss of $1.04 million. The company's balance sheet shows a total stockholders' deficit of $3.06 million, and it continues to manage significant liabilities from discontinued operations.

Key figure
Net loss $454K
4:03 PM ET 8-K
Other 8-K Filing CNO Financial Group, Inc. CNO

CNO Financial Group Other 8-K Filing

CNO Financial Group entered into a Sixth Amended and Restated Section 382 Rights Agreement to extend its existing 'poison pill' through November 13, 2029. The agreement is designed to protect the company's tax net operating loss carryforwards by deterring any person from acquiring 4.99% or more of the company's outstanding common stock without board approval.

Counterparty
Equiniti Trust Company, LLC
Term
3 years
4:03 PM ET Form 4
Insider Selling Appian Corp APPN

Appian Insider Mark Steven Lynch Sells $507K of Stock

Mark Steven Lynch sold 9,533 shares of Appian Corp at $53.14 a share, worth $507K in total on Nov 11, 2026. Shares held after the trade: 37,981 (-20.1%).

Value
$507K
Shares
9,533
Price
$53.14
Holding change
-20.1%
Trade date
Nov 11, 2026
4:02 PM ET Form 4
Insider Selling Sensata Technologies Holding plc ST

Sensata Technologies Holding EVP, Chief HR Officer Lynne J. Caljouw Sells $309K of Stock

Lynne J. Caljouw, EVP, Chief HR Officer, sold 7,726 shares of Sensata Technologies Holding plc at $40.02 a share, worth $309K in total on Nov 10, 2026. Shares held after the trade: 58,679 (-11.6%).

Value
$309K
Shares
7,726
Price
$40.02
Role
EVP, Chief HR Officer
Holding change
-11.6%
Trade date
Nov 10, 2026
4:02 PM ET 8-K
Leadership Change Moderna, Inc. MRNA

Moderna Leadership Change

Moderna's Chief Legal Officer, Shannon Thyme Klinger, will retire from the company effective March 31, 2027. Under a transitional services agreement, she will receive $1.63 million in severance plus potential performance bonuses of up to $8 million tied to the outcomes of ongoing litigation with Arbutus, Genevant, Pfizer, and BioNTech.

4:02 PM ET 10-Q
Financial Results CCS IX Portfolio Holdings, LLC

CCS IX Portfolio Holdings Q3 2026 Results: Net Income $20.9M, Up 309.2% YoY

CCS IX Portfolio Holdings, LLC reported a significant increase in total investment income to $58.6 million for the nine months ended September 30, 2026, compared to $18.5 million in the prior year period. Net assets grew to $732.4 million, driven by $353.3 million in capital contributions and $31.6 million in net increase in net assets from operations.

Key figure
Net income $20.9M · +309.2% YoY
4:02 PM ET 10-Q
Financial Results Dyadic International Inc DYAI ▶ Call

Dyadic International Q3 2026 Results: Net Loss of $1.36M, Loss Narrows

Dyadic International reported a net loss of $5.4 million for the nine months ended September 30, 2026, compared to $5.8 million in the prior year. The company is undergoing a strategic rebranding to Dyadic Applied BioSolutions, shifting focus from research to commercialized protein production platforms across life sciences and food sectors.

Key figure
Net loss $1.36M
4:02 PM ET 8-K
Nasdaq/NYSE Compliance Notice aTYR Pharma INC ATYR

aTYR Pharma Nasdaq/NYSE Compliance Notice

aTyr Pharma has regained compliance with Nasdaq's minimum bid price requirement after its common stock closed at or above $1.00 per share for 10 consecutive business days. The company had previously been under a deficiency notice since December 2025 and was granted an extension until November 30, 2026, to meet the standard. As of this filing, the company has no outstanding deficiency notices from Nasdaq.

Counterparty
Nasdaq
4:02 PM ET 10-Q
Financial Results Saga Communications Inc SGA

Saga Communications Q3 2026 Results: Net Loss of $7.09M, Loss Widens

Saga Communications reported a net loss of $7.1 million for the third quarter of 2026, primarily driven by a $9.2 million impairment of intangible assets. Net operating revenue decreased to $26.7 million from $28.2 million in the prior year period, while total assets declined to $183.0 million as of September 30, 2026.

Key figure
Net loss $7.09M
4:02 PM ET 10-Q
Financial Results Waterstone Financial, Inc. WSBF

Waterstone Financial Q3 2026 Results: Net Income $6.17M, Down 22.1% YoY

Waterstone Financial, Inc. reported net income of $20.6 million for the nine months ended September 30, 2026, an increase from $18.7 million in the prior year period. The company experienced a decrease in total assets to $2.25 billion, primarily driven by a reduction in loans held for sale and cash equivalents, while net interest income improved due to lower interest expenses on deposits and borrowings.

Key figure
Net income $6.17M · -22.1% YoY
4:01 PM ET 10-Q
Financial Results Spectral Capital Corp FCCN

Spectral Capital Q3 2026 Results: Net Loss of $3.37M, Loss Widens

Spectral Capital Corporation reported a significant revenue increase to $865.9 million for the nine months ended September 30, 2026, compared to $3.1 million in the prior year, primarily driven by business combinations. Despite the revenue growth, the company realized a net loss of $5.4 million for the period due to high cost of revenues and increased operating expenses.

Key figure
Net loss $3.37M
4:01 PM ET Form 4
Insider Selling Beta Bionics, Inc. BBNX

Beta Bionics CFO Stephen Feider Sells $153K of Stock

Stephen Feider, CFO, sold 8,874 shares of Beta Bionics, Inc. at $17.21 a share, worth $153K in total on Nov 11, 2026. Shares held after the trade: 159,378 (-5.3%).

Value
$153K
Shares
8,874
Price
$17.21
Role
CFO
Holding change
-5.3%
Trade date
Nov 11, 2026
4:01 PM ET Form 4
Insider Buying Drilling Tools International Corp DTI

Drilling Tools International CEO Robert Wayne Prejean Buys $17.7K of Stock

Robert Wayne Prejean, CEO, bought 10,000 shares of Drilling Tools International Corp at $1.77 a share, worth $17.7K in total on Nov 12, 2026. Shares held after the trade: 601,076 (+1.7%).

Value
$17.7K
Shares
10,000
Price
$1.77
Role
CEO
Holding change
+1.7%
Trade date
Nov 12, 2026
4:01 PM ET 10-Q
Financial Results Pmgc Holdings Inc. ELAB

Pmgc Holdings Q3 2026 Results: Net Loss of $2.41M, Loss Narrows

PMGC Holdings Inc. reported a significant revenue increase to $4.52 million for the nine months ended September 30, 2026, compared to $0.29 million in the prior year. However, net loss widened to $10.15 million due to increased operating expenses and interest costs, while the company underwent a series of reverse stock splits totaling 1-for-240.

Key figure
Net loss $2.41M
4:01 PM ET Form 4
Insider Buying Drilling Tools International Corp DTI

Drilling Tools International Director Eric C. Neuman Buys $66.3K of Stock

Eric C. Neuman, Director, bought 37,267 shares of Drilling Tools International Corp at $1.78 a share, worth $66.3K in total on Nov 12, 2026. Shares held after the trade: 378,789 (+10.9%).

Value
$66.3K
Shares
37,267
Price
$1.78
Role
Director
Holding change
+10.9%
Trade date
Nov 12, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.